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Abstract
Prion strain identification has been hitherto achieved using time-consuming incubation time determinations in one or more
mouse lines and elaborate neuropathological assessment. In the present work, we make a detailed study of the properties
of PrP-overproducing Tga20 mice. We show that in these mice the four prion strains examined are rapidly and faithfully
amplified and can subsequently be discriminated by a cell-based procedure, the Cell Panel Assay.
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Introduction
Transmissible spongiform encephalopathies (TSEs) or prion
diseases are characterized by the accumulation in the brain and
sometimes in the lymphoid tissues [1,2] of an abnormally
structured form (PrP
Sc) of the host prion protein (PrP
C) [3]. PrP
Sc
is thought to be the only [4] or the major [5–7] constituent of the
infectious agent, the prion. PrP
Sc is precipitable by sodium
phosphotungstate (NaPTA) and thought to comprise a proteinase
K-resistant and a proteinase K-sensitive fraction [8]. Prions occur
in the form of diverse strains exhibiting specific biological and
biochemical characteristics [9,10]. It is important to discriminate
between prion strains because they exhibit distinct interspecies
transmission properties, and in particular different pathogenicity
for humans [11,12]. Discrimination between strains has hitherto
been time-consuming and cumbersome, relying on the incubation
time (usually 5 months or more) in a panel of inbred mouse lines
and the determination of the lesion profile by semi-quantitative
assessment of vacuolation in nine regions of the brain grey matter
[13]. This method has been and still is the gold standard for strain
identification in murine models. However, the neuropathological
analysis is very demanding and relies on the experience of the
operator. The present study investigates the suitability of faster
approaches to the identification of murine prion strains.
Some 15 years ago it was shown that knocking out Prnp, the gene
encoding PrP, rendered mice resistant to prion infection and
incapable of propagating prions [14]. Importantly, introducing PrP-
encoding transgenes into the knockout mice restored susceptibility
to prions, a finding that enabled reverse genetics of Prnp [15]. The
murine Prnp transcription unit consists of 3 exons, of which the first
and second are separated by a 2-kb, and the second and third by a
10-kb intron. The coding sequence is contained entirely in the third
exon [16]. Because the transcription unit, even without the 59
flanking region, is 8–14 kb long [16,17], a construct devoid of the
large intron was prepared in order to facilitate modifications of the
transgene. Introduction of the resulting so-called pHG-PrP (‘‘half-
genomic PrP’’) construct into PrP knockout mice resulted in lines
with various copy numbers of the transgene which expressed PrP at
different levels, not necessarily in proportion to the copy number.
Mice overexpressing PrP exhibited shorter incubation times than
wild-type mice upon RML inoculation, but there was no direct
correlation with the level of expression. Of particular interest was
the line designated Tga20, which in the homozygous state contained
60 copies of pHG-PrP (ORF, haplotype a [18]), expressed PrP at
about 10 times the wild type level and succumbed to intracerebral
(i.c.) inoculation with RML prions, administered at a high dose (1%
brainhomogenate of a terminally sick wild-typemouse)within60+/
24 days, compared to 131+/29 days for wild-type mice [15].
Because of the reduced incubation times, Tga20 mice have been
extensively used for prion bioassays, both by the incubation time
method as well as by endpoint titration [19–22]. It has been shown
that PrP overexpression favors the intraneural spread of prions
[23] and the clinical expression of scrapie [22], and that the RML
and ME7 scrapie strains show different incubation periods in
Tga20 mice [24]. However, many features of Tga20 mice and their
response to prion infection have not been investigated, limiting
their use for accelerated strain identification. For example, it is not
known whether in these mice PrP is overexpressed in proportion to
wild-type levels in various brain regions. In particular, it is not
known whether different prion strains are propagated faithfully in
Tga20 mice, and if they give rise to patterns of PrP
Sc deposition
and histopathological changes similar to those in the C57BL/6
mouse widely used for strain typing.
In the present study we compared the expression pattern of
PrP
C in the brain of Tga20 mice and C57BL/6 qualitatively by
immunohistochemistry (IHC) and quantitatively by western blot
analysis. Because PrP
C is the substrate for the disease-associated
PrP
Sc, and because Tga20 mice succumb more rapidly to prion
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C
and PrP
Sc in wild-type and Tga20 mice. We then determined if
prion strains are propagated faithfully in Tga20 mice by the Cell
Panel Assay (CPA) [25]. We also investigated if different prion
strains can be distinguished by neuropathological criteria, in
particular whether vacuolation, gliosis and PrP
Sc deposition
patterns are similar to those in C57BL/6 mice.
Materials and Methods
Mouse bioassays
The use of animals was conducted according to institutional
guidelines after review of the protocol by the Institutional Animal
Care and Use Committee. Mice were anesthetized by isoflurane
and inoculated in the prefrontal cortex area with 20 mlo f1 %
brain homogenate. They were euthanized by CO2 followed by
cervical dislocation when they showed pronounced clinical signs,
manifested by ataxia, a hunched back, loss of appetite, and a
matted hair coat, prior to terminal symptoms.
Blinded study
Two or three sections of Tga20 mouse brain, uninfected or
infected with RML, ME7, or 22L, were prepared and coded by
AS. Immunohistochemical staining as described below and strain
identification were performed blind by YK.
Histological and immunochemical procedures
All procedures were carried out at room temperature unless
indicated otherwise.
General procedures. Brains and spleens were fixed in
Carnoy’s fixative for 24 h and stored in butanol until paraffin
embedding. Tissue sections (4–7 mm) were dried at 60uC for 1 h,
deparaffinized in xylene, rehydrated in graded alcohols and
washed in distilled water. Routine staining was with Mayer’s
hemalaun and eosin.
Immunofluorescent detection of PrP
C (Fig. 1).
Rehydrated sections were treated with 10 mg/ml proteinase K
(PK; Roche) in 50 mM Tris-HCl (pH 7.4), 0.5 mM EDTA for
5 min, in order to enhance the immunoreactivity of PrP, rinsed in
cold water, and treated with 4 M guanidinium thiocyanate for
10 min. Sections were then washed twice in distilled water, twice
in PBS, once in PBST (0.1% Triton X-100 in PBS) and incubated
for 2 h with D18 monoclonal anti-PrP antibody [46] which was
directly labeled with Alexa 555 fluorophore (5 mg/ml; Alexa Fluor
555 monoclonal antibody labeling kit, Invitrogen) in PBS. After
washing twice in PBS, sections were mounted in Vectashield
(Vector). Images were taken through an epifluorescence Zeiss
microscope (AxioZeiss, Imager.A1) (http://www.zeiss.com/)
equipped with an AxioCam MRc camera, using AxoVision
software version 14, and processed with Adobe Photoshop (CS2,
Version 9.0.2)
Figure 1. The PrP
C expression pattern in different brain regions of Tga20 mice differs from that in C57BL/6 mice. PrP
C expression in six
brain regions was monitored using Alexa 555-labeled D18 anti-PrP antibody in six brain regions: A, cortex; B, cerebellum; C, brain stem; D, striatum;
E, thalamus. All photos except the ones labeled ‘‘C57+’’ were taken at the same settings. ‘‘C57+’’ are photos of the same area as ‘‘C57’’, but taken at
longer exposures. F,G: PrP
C expression in Purkinje cells. PrP
C and calbindin in the cerebellum were immuno-labeled using Alexa 555-tagged D18 anti-
PrP antibody (red) and Alexa 488-tagged anti-calbindin rabbit polyclonal antibody (green), respectively. F: C57BL/6 mouse cerebellum, G: Tga20
mouse cerebellum. PrP
C is stained red, calbindin green. The overlay on the right shows PrP
C-expressing Purkinje cells in yellow. M, molecular layer; G,
granular layer of the cerebellum; P, Purkinje cell layer. Bars represent 20 mm.
doi:10.1371/journal.pone.0005730.g001
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C and calbindin in Purkinje
cells. For fluorescence double-labeling studies rehydrated
sections were pretreated and stained with Alexa 555-labeled D18
monoclonal anti-PrP antibody as described above, followed by 2 h
incubation with anti-calbindin rabbit polyclonal antibody (Sigma),
labeled with Alexa 488 fluorophore using the Zenon kit (Zenon
Tricolor Rabbit IgG Labeling kit#2, Invitrogen), at 1 mg/ml in
PBS. After incubation, sections were washed twice in PBS and
mounted in Vectashield (Vector). Confocal images were taken with
an Olympus confocal laser scanning microscope (U-TBI90) using
FLUOVIEW FV1000 software and processed with Adobe
Photoshop (CS2, Version 9.0.2).
Immunohistochemical detection of PrP
Sc. Rehydrated
brain sections were treated with 1.5% hydrogen peroxide in
methanol to inactivate endogenous peroxidase and subjected to
pretreatment as described above for immunofluorescent studies.
No pretreatments aimed at eliminating PrP
C were used; disease-
associated PrP deposits (called PrP
Sc in the present study) in
infected mouse brains showed a distinctly different appearance
after immunostaining than PrP
C, which, if at all, appeared as faint
homogenous background staining. After incubation with the anti-
PrP antibody Bar233 (Spibio) at 0.1 mg/ml in PBS for 2 h,
sections were washed with PBS, incubated with anti-mouse IgG
peroxidase-coupled polymer ImmPRESS (Vector) for 10 min and
followed by the chromogen VECTOR NovaRed (Vector) for
5 min. Slides were lightly counterstained with Mayer’s hemalaun
(4 min), dehydrated, and mounted with Vectamount (Vector).
GFAP immunohistochemitry. Astrocytes were stained with
anti-GFAP rabbit polyclonal antibody (Sigma, 1:1000 in PBS) for
1 h followed by anti-rabbit IgG peroxidase-coupled polymer
ImmPRESS (Vector) for 15 min. Peroxidase activity was detected
as above.
PET-BLOT procedure
Brains were fixed in Carnoy’s fixative for 24 h, transferred to
butanol and embedded in paraffin. Sections (4 mm) were mounted
onto nitrocellulose membranes, baked at 50uC for 1 h, depar-
affinized by two successive 10-min incubations in xylene, followed
by successive incubations in 100%, 80% and 50% isopropanol for
5–10 min each. After rehydration with TBST (0.1% Tween in
10 mM Tris-Buffered Saline) for 5 to 10 min, sections were
digested with 20 mg of PK/ml in TBST for 1.5 h, washed 10 min
in TBST-PMSF, then 3 times 5 min in TBST. The membranes
were incubated for 10 min in 3 M guanidinium thiocyanate,
washed 3 times for 5 min in TBST, and blocked for 1 h in 5%
milk- TBST. Immunodetection was performed by incubation for
1 h with the anti-PrP D18 antibody at 1:3,000 in 2% milk –
TBST, followed by three 5-min washes with TBST and incubation
for 1 h with murine HRP-conjugated anti-human IgG antibody at
a 1:8,000 dilution (Southern Biotech). After two washes in TBST,
the blots were developed with DAB (Vector Labs.) as a substrate,
dried and photographed using a stereomicroscope (Zeiss).
Biochemical analysis of PrP
C and PrP
Sc
Preparation of tissue homogenates. Brains were perfused
with PBS, 5 mM EDTA prior to harvesting. For the experiments
of Fig. 2 A and D, 10% w/v homogenates were prepared in PBS
containing 150 mM NaCl, 1% Triton X-100 and the complete
TM
cocktail of protease inhibitors with EDTA (Roche, Indianapolis,
IN). For the experiments of Fig. 2 B and C, 5% w/v homogenates
were prepared in 50 mM Tris-HCl (pH 8) containing 150 mM
NaCl, 0.5% Triton X-100 and 0.5% sodium deoxycholate.
Homogenates were centrifuged at 1,500 rpm for 30 sec in an
Eppendorf centrifuge (Hamburg, Germany, model 5414). For the
experiments of Table 1, the appropriate regions were dissected
from three fresh mouse brains immediately after collection and
frozen at 280uC. Homogenates were prepared as described for
Fig. 2 A and D.
Enzymatic digestion of brain homogenates. Brain
homogenates prepared as described above for Fig. 2 B and C
were incubated with 25 mg of TL or PK/ml for one hour at 70 or
37uC, respectively. The 5% brain homogenates contained on
average 5 mg of protein per ml; the exact protein content was
determined for each sample by the BCA test (Pierce) in order to
standardize the quantification of the western blot signal per mgo f
protein.
Western blot analyses and signal quantification. Proteins
(in NuPAGE LDS sample buffer, Invitrogen, containing 3%
mercaptoethanol) were fractionated by SDS-polyacrylamide gel
electrophoresis, electroblotted onto a nitrocellulose membrane
(Whatman Inc. USA) and probed with D18 antibody at a 1:30,000
dilution followed by a murine HRP-conjugated anti human IgG
antibody at a 1:15,000 dilution (Southern Biotech), or with the
Pri308 antibody at a 1:10,000 dilution, followed by a goat HRP-
conjugated anti mouse IgG antibody at a 1:15,000 dilution
(Southern Biotech). Immunoreactive bands were visualized by
West Pico (Pierce, Rockford, IL) and exposure to X-ray film (GE
Healthcare, Piscataway, NJ), and quantified by UVP
(BioSpectrumHAC Imaging System).
Proteinase K digestion of PrP27-30. PrP
Sc was precipitated
from 22L, RML and ME7-infected brains by the NaPTA
procedure [47]. NaPTA pellets obtained from 500 ml of 10%
brain homogenates were resuspended in 10% PrP
o/o brain
homogenate (containing on average 10 mg/ml of protein) and
digested with 50 mg PK/ml (final concentration) for 1 h at 56uC
and 450 rpm in a Thermomixer R (Eppendorf), to yield PrP27-30.
Aliquots of PrP27-30, were incubated with PK at concentrations
ranging from 100 to 3,200 mg/ml for 1 h at 37uC. PrP27-30 was
quantified by western blot analysis.
Cell Panel Assay
Cell lines were maintained and the Cell Panel Assay was
performed as described in [25] except that the assays with LD9
cells were under conditions that rendered them susceptible to




Western blot analysis showed that PrP
C levels in Tga20 relative
to C57BL/6 mice were approximately 5 to 20-fold higher,
depending on the brain region (Table 1). Immunohistochemical
analysis revealed a higher intensity of staining of intracellular
PrP
C, PrP
C of the neuropil and PrP
C associated with the white
matter tracts (Fig. 1 A–E). Strikingly, cerebellar Purkinje cells of
Tga20 mice fail to express PrP
C (Fig. 1 B, G), reflecting the
absence of PrP mRNA reported earlier [14]. Purkinje cells of
C57BL/6 and CD1 mice (Figs. 1 B, F and data not shown) express
PrP
C, albeit not in all areas of the cerebellum [26].
Biochemical properties of PrP
C and PrP
Sc in Tga20
compared to C57BL/6 mice
To compare the resistance to proteinase K (PK) of PrP
C from
uninfected Tga20 and wild type mice, we diluted Tga20 brain
homogenates 1:8 into PrP
0/0 brain homogenate to achieve the
same concentration of PrP
C as in homogenates of C57BL/6 mice
(Fig. 2 A1). The homogenates (containing on average 10 mg
protein/ml) were digested with PK at 40 mg/ml for various times
Prion Strain Identification
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C and PrP
Sc from Tga20 and C57BL/6 brains. All samples were analyzed by western blotting and the
quantification of the blots is summarized in Table 2. A. PK digestion of PrP
C.A 1 :Uninfected Tga20 brain homogenates were diluted 1:8 into PrP
o/o
brain homogenate to adjust PrP
C to the same levels as in C57BL/6 homogenates. Serial 1:2 dilutions of the two preparations, compared by western blot
analysis, showed indistinguishable PrP
C levels. A2: C57BL/6 and 1:8 diluted Tga20 brain homogenates were digested for the times indicated with 40 mg
PK/ml at 56uC. A3: The same samples as in (A2) were digested with PK at the concentrations indicated at 37uC for 60 min. B: Thermolysin digestion of
brain homogenates from C57BL/6 or Tga20 mice infected with 22L, RML or ME7. Homogenates were treated with 25 mg TL/ml for one hour at 70uC and
Prion Strain Identification
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50 mg/ml (Fig. 2, A3). Interestingly, PrP
C from Tga20 mice was
more resistant to PK than PrP
C from C57BL/6 mice in both
experiments. Maybe PrP
C produced at high levels aggregates,
perhaps in the form of aggresomes, and thereby become less
susceptible to PK digestion. Cytoplasmic, toxic forms of PrP have
been shown to accumulate in aggresomes [27–29]. In contrast,
PrP27-30, the PK-treated moiety of PrP
Sc, from Tga20 and
C57BL/6 mice infected with the various strains, showed no
difference in resistance to further digestion with PK, at
concentrations up to 3,200 mg/ml (Fig. 2 D).
Brain homogenates from Tga20 mice infected with 22L, RML
and ME7 contained 2.4, 1.5 and 1.3 times, respectively, more total
PrP, i.e. PrP
C plus PrP
Sc, than those from C57BL/6 mice (Fig. 2
B, C, data not shown and Table 2), which is not in proportion to
the eightfold PrP
C overexpression in uninfected Tga20 mice. The
increase of total PrP in infected C57BL/6 mice is most likely due
to a doubling of the PrP
C level [30] in addition to the
accumulation of PrP
Sc; in infected Tga20 mice there is little PrP
Sc
(see below) and possibly no increase of PrP
C, hence less increase of
total PrP.
PrP





Sc) moieties [8]. SenPrP
Sc was claimed to be resistant
to thermolysin (TL) treatment under conditions allowing complete
PrP
C digestion [31,32]. We analyzed by western blot the
proportions of TL- and PK-resistant PrP in the brains of
C57BL/6 as compared to Tga20 mice infected by the 22L,
RML and ME7 strains (Fig. 2 B, C, Suppl. Fig. 3 and Table 2).
Brains of 22L-infected Tga20 mice harbored 5 times less PK-
resistant PrP than those of C57BL/6 mice. Only 4 and 2% of the
PrP in Tga20 mouse brain were resistant to TL and PK,
respectively, as compared to 11 and 22% in C57BL/6 mice.
Brains of ME7-infected Tga20 mice contained 4–5 times less TL-
and PK- resistant PrP than those of C57BL/6 mice, i.e. only 1 and
4% of the PrP in Tga20 mouse brain were resistant to TL or PK,
respectively, as compared to 7 and 29% in C57BL/6 mice. On the
other hand, brains of RML-infected Tga20 mice contained only
marginally less TL- and PK-resistant PrP than those of C57BL/6
mice. In summary, the amounts of TL- and PK-resistant PrP are
strain-dependent not only in wild-type mice but also in Tga20
mice. Moreover, Tga20 mice, despite higher PrP
C expression
levels, accumulated less PrP
Sc than wild-type mice with all strains,
showing an intrinsic limitation in PrP
Sc levels in Tga20 mice.
The specific infectivities of resPrP
Sc, as determined by the SSCA
using LD9 cells [25], differ between strains and mouse lines
(Table 2). This underlines the previously described observation
that resPrP
Sc is an unreliable indicator of infectivity [33–36].
Faithful propagation of prion strains
Different strains of prions exhibit cell-specific tropism that can
be assessed in vitro by the Cell Panel Assay (CPA) [25]. This assay is
based on a sensitive, accurate and rapid cell-based procedure for
quantification of prion infectivity, the Standard Scrapie Cell Assay
(SSCA) [37]. Cells are exposed to prions, passaged for three splits,
immunostained for PrP
Sc, and individual, PrP
Sc-containing cells
are counted using automated imaging equipment. The response of
a cell line to a prion strain is expressed by the Response Index (RI),
the concentration of the sample required to give a designated
proportion of infected cells (usually taken as 1.5%) under
standardized conditions. Prion strains can be characterized by
the ratio of their RI’s on four cell lines, PK1, CAD5, LD9 and
R33; this panel allows discrimination of RML, ME7, 301C and
22L prions [25].
C57BL/6 and Tga20 mice inoculated with these four strains
(using 20 ml of 1% brain homogenates of terminally sick wild-type
mice) were sacrificed when they showed advanced clinical
symptoms. Table 3 shows that incubation times were shortened
for Tga20 mice, but remarkably to different extents for the various
strains, ranging from a reduction of 85 days or 59% for RML to
only 36 days or 22% for 301C. Brain homogenates were subjected
to the CPA; as shown in Fig. 3, the RI values on PK1, CAD5 and
R33 cells relative to those on LD9 cells were the same for C57BL/
6 and Tga20, within the limits of error. Thus, the four strains we
examined had the same CPA characteristics whether they were
propagated in Tga20 or in C57BL/6 mice. Interestingly, the RI
values were 3 to 12 times lower for strains propagated in Tga20
than for C57BL/6 brains (Fig. 3 and Supplem. Table) except for
301C, which had an equal or higher RI in Tga20 than in C57BL/
6 mice; this may be due to the relatively long incubation time for
301C in Tga20, allowing for more extensive replication.
Comparison of disease-associated PrP deposition and
histopathology in Tga20 and C57BL/6 mice
The neuropathological and immunohistochemical phenotype
elicited by the three prion strains ME7, RML and 22L in Tga20
differed from that in C57BL/6 mice. This is exemplified by PET-
BLOT images of brain sections which showed strikingly lower
cortical, hippocampal and cerebellar PrP
Sc signal intensities in
22L-infected Tga20 than in C57BL/6 mice (Fig. 4 F). Although
overexpressing PrP
C, Tga20 mice accumulated less PrP
Sc, in this
context defined as PrP stained immunohistochemically in infected
brain under conditions where there is no or only faint background
staining in uninfected controls (Fig. 4 A–E and Fig. S1). This is in
good agreement with the results of the biochemical PrP analyses
described above. However, there were strain-dependent differenc-
es between the different brain regions. The brainstem (Fig. 4 B)
and thalamus (Fig. S1) exhibited PrP
Sc deposition of similar
intensity in Tga20 and C57BL/6 mice, which was found with all
the strains examined. Hallmarks of the ME7 strain in Tga20 mice
Table 1. Expression levels of PrP
C in different brain regions of







Brains were harvested from 3 healthy female C57BL/6 and Tga20 mice (6–12
weeks of age), and the regions indicated were immediately dissected and
pooled. PrP
C in Tga20 mice was quantified relative to that in C57BL/6 mice by
western blot analysis of the cognate homogenates.
doi:10.1371/journal.pone.0005730.t001
serial dilutions analyzed. C: Proteinase K digestion of brain homogenates from C57BL/6 or Tga20 mice infected with 22L, RML or ME7. Homogenates
were treated with 25 mg PK/ml for one hour at 37uC andserial dilutions were analyzed. D: Proteinase K digestion of 22L-, RML- or ME7-derived PrP27-30.
PrP27-30 was prepared as described in the Methods section and digested with the PK concentrations indicated for 60 min at 37uC.
doi:10.1371/journal.pone.0005730.g002
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Sc plaques in the cortex and hippocampus. A
characteristic of 22L infection in Tga20 mice was the presence of
plaque-like PrP
Sc deposits in the granular layer of the cerebellum
(Table 4). None of those features were observed in the four RML-
infected Tga20 brains examined, which exhibited diffuse PrP
Sc
deposits in the cortex, hippocampus and brainstem.
Table 2. PrP levels in prion-infected brains of C57BL/6 and Tga20, and specific infectivities of PK-resistant PrP.
PrP in 22L-infected mouse brains (arbitrary units/mg protein)
Preparation C57BL/6 (%) Tga20 (%) Tga20/C57BL/6
Total PrP 18471 (100) 45243 (100) 2.4
TL-resistant PrP 2050(11) 1606 (4) 0.8
PK-resistant PrP 4137 (22) 742 (2) 0.18
Ratio TL/PK 1:2 2.2:1
PrP in RML-infected mouse brains (arbitrary units/mg protein)
Preparation C57BL/6 (%) Tga20 (%) Tga20/C57BL/6
Total PrP 15140 (100) 23392 (100) 1.5
TL-resistant PrP 2169 (14) 1823 (8) 0.84
PK-resistant PrP 1384 (9) 1258 (5) 0.91
Ratio TL/PK 1.6:1 1.4:1
PrP in ME7-infected mouse brains (arbitrary units/mg protein)
Preparation C57BL/6 (%) Tga20 (%) Tga20/C57BL/6
Total PrP 17411 (100) 23200 (100) 1.3
TL-resistant PrP 1184 (7) 271 (1) 0.23
PK-resistant PrP 5032 (29) 951 (4) 0.19
Ratio TL/PK 1:4.3 1:3.5
Specific infectivity of PK-resistant PrP (RI/resPrP
Sc)*
Strain C57BL/6 Tga20 Tga20/C57BL/6
22L 56 90 1.6
RML 66 15 0.2
ME7 16 14 0.9
The PrP content of brain homogenates was assessed by western blot and quantification of immunoreactive bands in arbitrary pixel units by UVP (BioSpectrumHAC
Imaging System). Each measurement was adjusted for gel loading to provide the pixel value per mg of sample protein. All gels have been normalized to each other
allowing the comparison of PrP values. TL- and PK-resistant PrP values have been calculated using regression curves of signal intensities obtained on serial dilutions of
each sample (Fig. 2 B and C and Fig. S3).
*The specific infectivity of resPrP
Sc is herein defined as the ratio of the RI measured in LD9 cells (susceptible to all three prion strains) relative to resPrP
Sc (pixels per ng of
brain protein, see above).
doi:10.1371/journal.pone.0005730.t002
Table 3. Characteristic parameters of various prion strains in C57BL/6 and Tga20 mice.
Survival times
+ Titer




RML 14465.5 (48) 59 (8) 85 0.41 8.75
22L 13561.5 (45) 83 (3) 52 0.61 8.26
ME7 14366 (49) 94 (3) 49 0.68 8.26
301C 16261.4 (15) 126 (3) 36 0.78 n.d.
+Mice were inoculated with 20 ml of 1% brain homogenate and euthanized when they showed pronounced clinical signs, rather than at terminal stage of disease. The
average incubation period for ME7 in C57BL/6 mice is shorter than the 155–160 days described in some other studies [24,48,49]. This might be due to variations in the
criteria for euthanasia, the number of passages of the strain and/or variations between different C57BL/6 mouse lines.
{Because of the very short symptomatic period in Tga20 mice, all mice in a group were killed on the same day.
#By endpoint titration in C57BL/6 mice (6 mice per group, 22L and ME7; 5 mice per group, RML) [50]. The inocula were homogenates of brains from terminally sick
C57BL/6 mice infected with 22L, ME7 or 301C, or from terminally sick CD1 mice infected with RML.
doi:10.1371/journal.pone.0005730.t003
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5730Figure 3. The Cell Panel Assay of four prion strains propagated in Tga20 or wild-type mice results in similar relative Response
Indices on four cell lines. CAD5 (red), PK1 (blue), R33 (green) and LD9 (violet) cells were exposed to 1:3 serial dilutions of 0.1% brain homogenates
infected with 22L (a,b), RML (c,d), ME7 (e,f) or 301C (g,h) propagated in Tga20 mice (a,c,e,g) or wild-type mice (b, f, h, C57BL/6; d, CD1). The number of
PrP
Sc-positive cells (‘‘spots’’) is plotted against log[dilution] of the brain homogenate. The Response Index (RI1.5%/3) of a cell line for a prion strain
(vertical dotted line) is the concentration (reciprocal of the homogenate dilution) that yields 300 spots per 20’000 cells (1.5% PrP
Sc-positive cells) after
the 3
rd split (horizontal dotted line). The ‘‘RI ratio’’ of a strain is the RI on a cell line relative to that on LD9; it was very similar for each strain regardless
of whether it was propagated in wild-type or Tga20 mice (see Table S1 for RI values).
doi:10.1371/journal.pone.0005730.g003
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Sc deposition pattern in C57BL/6 and Tga20 mice infected with three scrapie prion strains. Although PrP
C levels are higher
in all brain regions of Tga20 as compared to C57BL/6 mice, PrP
Sc levels were lower in Tga20 mice except for the brainstem and thalamus (see also Fig.
S1). PrP
Sc was detected by IHC using anti-PrP mouse monoclonal antibody Bar 233 (SpiBio) and secondary anti-mouse IgG antibody, as described in
the methods section. Bar 233 stains PrP
Sc deposits with various morphologies in the brains of C57BL/6 and Tga20 mice infected with ME7, 22L and
RML scrapie strains. Only faint diffuse cytoplasmic and neuropil staining was seen in uninfected mouse brains (Fig. S1). The secondary antibody alone
stains only plasma in the blood vessels, as can be seen in large vessels in the last pictures on the right of A, D and E. A, striatum; B, brain stem; C,
cortex; D, cerebellum; E, hippocampus. Table 4 summarizes the findings. Bars represent 50 mm. F: PET-BLOTS of horizontal brain sections from Tga20
and C57BL/6 mice infected with the 22L strain and the corresponding uninfected control mice. Arrows show the cortexes, hippocampi and cerebella.
doi:10.1371/journal.pone.0005730.g004
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mice varied to some extent for each prion strain. However, they
were not distinctive enough to identify strains with confidence
using conventional lesion profiles (Table 5). On the other hand,
PrP
Sc deposition profiles in Tga20 mice were substantially different
between the strains 22L, ME7 and RML and did not correlate
with the level of PrP
C overexpression in these mice (Tables 1, 5
and Fig. 5). A blinded analysis of a panel of slides by one of us
(Y.K.) demonstrated that it was possible to reliably distinguish
these strains on the basis of PrP
Sc immunohistochemistry.
In conclusion, 22L, ME7 and RML prions propagated in Tga20
mice retain their characteristic tropism for cultured cells, allowing
their distinction by the Cell Panel Assay. While conventional lesion
profiling seems not to be feasible, immunohistochemistry reveals
characteristic differences in the location and pattern of PrP
Sc
deposits. Thus, Tga20 mice allow not only accelerated infectivity




Sc deposits in the granular layer of the cerebellum + 22
Dense PrP
Sc plaques in the cortex and hippocampus 2 + 2
PrP
Sc staining of cerebellum + 22
Diffuse PrP
Sc deposits in cortex and hippocampus + 2 +
doi:10.1371/journal.pone.0005730.t004
Table 5. Comparative neuropathology in Tga20 and C57BL/6 mice infected with three prion strains.
ME7 C57BL/6 Tga20
Spongiosis Gliosis PrP
Sc Spongiosis Gliosis PrP
Sc
Cortex +++ +++ ++++ + + +
Hippocampus +++ ++++ ++++ + ++ ++
Cerebellum +++ ++ +++ 2 + 2
Brainstem ++ +++ +++ +++ ++++ +++
Thalamus ++++ +++ +++ ++++ ++++ +++
Striatum ++ +++ +++ 22 2
Septum +++ +++ +++ ++ ++ ++
22L C57BL/6 Tga20
Spongiosis Gliosis PrP
Sc Spongiosis Gliosis PrP
Sc
Cortex +++ +++ ++++ + + +
Hippocampus ++ ++++ ++++ ++ ++ +
Cerebellum ++++ ++++ ++++ + ++ ++
Brainstem +++ ++++ +++ +++ +++ +++
Thalamus ++ +++ +++ +++ +++ ++
Striatum + + +++ 22 2
Septum ++ +++ +++ + + +
RML C57BL/6 Tga20
Spongiosis Gliosis PrP
Sc Spongiosis Gliosis PrP
Sc
Cortex ++ ++++ ++++ + + +
Hippocampus ++ ++++ ++++ + + +
Cerebellum +++ +++ ++++ 2 + 2
Brainstem +++ +++ ++++ ++ +++ +++
Thalamus ++ +++ ++++ +++ ++++ +++
Striatum + ++++ ++++ 2 ++ +
Septum + ++++ ++++ 22 2
The severity of spongiform changes, astrogliosis and PrP
Sc deposition are indicated as follows: 2, none; +, slight; ++, moderate; +++, severe; ++++, very severe. PrP
Sc is
defined as PrP immunoreactive material which is not observed in similarly processed sections from uninfected mice, and its overall intensity was visually assessed
regardless of the morphology of the deposits (described in Table 4).
doi:10.1371/journal.pone.0005730.t005
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5730determination, but also strain discrimination, at least for the strains
examined in the present study.
Discussion
Our endeavor to characterize Tga20 mice in terms of their PrP
expression and their response to prion infection led us to a number
of interesting observations.
We found that overexpression of PrP
C in Tga20 brains is not
homogeneous,incontrastto itsexpression inthebrains ofC57BL/6
mice. While some regions, in particular brainstem, highly
overexpress PrP
C, others, such as cortex and striatum, express only
moderately higher levels of PrP
C (Fig. 5). However we found no
detectable expression in Tga20 cerebellar Purkinje cells, in
agreement with the previously reported absence of PrP mRNA
[15]. The expression of PrP
C by Purkinje cells in wild-type mice has
been the subject of discordant reports [26,38–41]. We confirm that,
as described previously [26,41], wild-type mice express PrP in
Purkinje cells,albeitnot homogeneouslythroughoutthecerebellum.
The PrP
C expression pattern does not correspond to a clear
anatomical distribution [39] and the reason for the heterogeneity of
Purkinje cells with regard to PrP
C expression in wild-type mice
remains unknown. The absence of PrP
C and PrP mRNA in
Purkinje cells as well as the variable overexpression levels of PrP
C in
different brain areas of Tga20 mice remain unexplained. PrP
C
expression was also markedly different in the spleens of Tga20 and
wild-type mice; we detected PrP
C only in the red pulp but not in the
follicular germinal centers of the transgenic animals, whereas in
wild-type mice PrP
C is localized in the germinal centers (Fig. S2 and
[42]). One hypothesis is that the PrP
C expression pattern in Tga20
mice is altered due to the deletion of the large intron from the PrP
gene construct. Alternatively, or in addition, the integration site of
the transgenes could modulate expression. It should also be noted
that the pHG expression construct used in these transgenic mice is,
lamentably, heterogeneous in regard to its constituent segments: the
promoter region, the 1
st exon as well as the intron and its flanking
spliceregions arederived from I/LN mice (Prnp
b), most ofthe59 and
39 non-coding regions as well as the ORF are from NMR1 mice
(unknowm Prnp haplotype) and the 39 part of the 39 non-coding and
the 39 flanking region are from NZW/lac mice (Prnp
a) [15].
The CPA provides an alternative, novel and rapid method for
strain discrimination [25]. It is based on strain-specific tropism
that enables prions to chronically infect some cell lines but not
others. The molecular basis for this strain-specific characteristic
might be similar to that underlying the brain tropism trait that is
exploited to identify strains on the basis of the lesion profiles [43].
We determined that the four strains examined in this study
retained their characteristic behavior in the CPA after being
replicated in Tga20 mice, despite the fact that the lesion and PrP
Sc
deposition profiles were different than in wild-type mice. In
addition, the PrP
Sc deposition profiles in Tga20 mouse brains were
sufficiently different for 22L, ME7 and RML prions to allow clear
discrimination between these three strains.
As shown in Table 3, the time elapsing between inoculation and
terminal disease (‘‘incubation time’’) is shorter in Tga20 than in
C57BL/6 mice, albeit not to an equal extent for the different
Figure 5. PrP
Sc deposition does not correlate with PrP
C overexpression in Tga20 mice and is strain specific. Schematic drawing of
selected brain regions showing the intensity of PrP
C overexpression (top row), PrP
Sc deposition for three different scrapie strains (middle row) and the
merged view (bottom row). PrP
C is shown in blue, PrP
Sc in red. This scheme summarizes the data described in Fig. 1, Table 1 (PrP
C), Fig. 4, Fig. S1,
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about 2 weeks in wild-type mice to a few days in Tga20 mice. Our
studies and those of others [15,24] rule out overall higher levels of
cerebral PrP
Sc as a reason for accelerated pathogenesis and
disease, and support the hypothesis that a specific vital brain
region (‘‘clinical target area’’ [44,45]) may be preferentially
affected. In fact, as shown by immunohistochemistry, PrP
Sc
accumulates at lower levels in all brain regions of Tga20 except
for the brainstem and thalamus, which show intense PrP
Sc staining
with all prion strains examined (Fig. 4 and Fig. S1), suggesting that
one or both of these may be the clinical target areas.
It remains to be explained why PrP
C, which is abundantly
present in most brain regions of Tga20 mice, largely fails to be
converted into PrP
Sc. One suggestion has been that PrP
Sc
generated in Tga20 mice may be sensitive to PK digestion [24],
another, that the increased rate of synthesis of PrP
C results in
improperly folded, perhaps aggregated PrP which is not suitable
for conversion to PrP
Sc, or which accumulates in an inappropriate
compartment, such as the aggresome [27–29]; our finding that
PrP
C in uninfected Tga20 brains is more resistant to digestion by
PK than its wild-type counterpart may provide some support for
the latter view. A more likely explanation, however, is that less
PrP
Sc and infectivity accumulate in Tga20 mice because of their
shortened survival time. This hypothesis is supported by the fact
that lower infectivities in Tga20 mice were observed by the CPA
for RML, 22L and ME7, which showed strong reductions in
incubation times, but not for 301C, which showed only moderate
reduction.
Because of the inhomogenous overexpression of PrP
C in
different brain regions, Tga20 mice provided a unique opportunity
to study the relationship between PrP
C expression levels and PrP
Sc
accumulation. Interestingly, except for the presumed clinical target
areas brainstem and thalamus, PrP
Sc accumulation patterns do not
follow PrP
C overexpression (Fig. 5). For example, the cerebellum
expresses higher PrP
C levels than the cortex in Tga20 mice, yet
there is virtually no PrP
Sc deposition for two of three strains. This
once more raises the question as to the factors underlying the
different tropism exhibited by the various strains.
Finally, of practical importance, the prion strains we examined
retain their identity after propagation in Tga20 mice and can be
discriminated by the CPA as well as by immunohistochemical
analysis of PrP
Sc deposits, reducing the time required for analysis
by months.
Supporting Information
Figure S1 PrPSc deposition pattern in the thalamus of C57BL/6
and Tga20 mice infected with three scrapie prion strains and PrPC
staining in the thalamus of uninfected control mice. PrPC and
PrPSc were detected by IHC using anti-PrP mouse monoclonal
antibody Bar 233 (SpiBio) and secondary anti-mouse IgG
antibody. Bar 233 stains PrPSc deposits with various morphologies
in the brains of C57BL/6 and Tga20 mice infected with ME7,
22L and RML scrapie strains. Only faint diffuse cytoplasmic and
neuropil staining was seen in uninfected mouse brains. Bars
represent 20 mm (ME7) or 50 mm (22L, RML and uninfected).
Found at: doi:10.1371/journal.pone.0005730.s001 (3.31 MB TIF)
Figure S2 PrPC in spleens of C57BL/6 and Tga20 mice. PrP
was stained using the monoclonal antibody D18. General
procedures were similar to those described for the processing of
brain tissue. The differences were that tissue pretreatment
consisted only of exposure to guanidinium thiocyanate without
PK treatment, and D18 anti-PrP antibody was used at 5 mg/ml for
2 h followed by washes with PBS and incubation with secondary
anti-human IgG linked to HRP (Southern Biotech) at 1 mg/ml for
2 h. A, C : PrPC in the spleens of C57BL/6 is seen in the germinal
centers of follicles. B, D : PrPC is not detectable in the follicles of
Tga20 mouse spleens, but can be seen in the interfollicular zones
(red pulp). Bars represent 100 mm (upper panels) or 20 mm (lower
panels).
Found at: doi:10.1371/journal.pone.0005730.s002 (4.05 MB TIF)
Figure S3 Quantification of TL- and PK-resistant PrP. UVP
quantification data of PrP immunoreactive bands, expressed in
arbitrary pixel units, were plotted against the sample concentra-
tion. Regression curves show good signal linearity over the dilution
series. The ratio of PK- or TL-resistant PrP in C57BL/6 versus
Tga20 mice is calculated from the ratio of the slopes of the
corresponding regression lines.
Found at: doi:10.1371/journal.pone.0005730.s003 (0.58 MB TIF)
Table S1 RIs
Found at: doi:10.1371/journal.pone.0005730.s004 (0.15 MB TIF)
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